The global market for Self Amplifying RNA Vaccine was valued at US$ 417 million in the year 2024 and is projected to reach a revised size of US$ 587 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Self Amplifying RNA Vaccine Market

Self-amplifying RNA vaccine, or SAM vaccine, is an innovative vaccine type based on mRNA technology. Compared with conventional mRNA vaccines, self-amplifying RNA vaccines can replicate and express antigen proteins within cells, significantly increasing antigen production and duration, and enhancing immune responses. This vaccine uses vectors such as alphaviruses to introduce mRNA encoding antigen proteins into human cells, where they replicate and express to form large amounts of antigen proteins, subsequently inducing a strong immune response in the human body. Self-amplifying RNA vaccines offer advantages such as simple production processes, easy scalability, and rapid response to viral mutations, providing a powerful tool for addressing emerging and sudden infectious diseases.

North American market for Self Amplifying RNA Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Self Amplifying RNA Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Self Amplifying RNA Vaccine include Arcturus Therapeutics, CSL, Gennova Biopharmaceuticals, Genvax Technologies, Merck Animal Health, VLP Therapeutics, Chimeron Bio, Eyam Vaccines and Immunotherapeutics, Ziphius, Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Self Amplifying RNA Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Self Amplifying RNA Vaccine.

The Self Amplifying RNA Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Self Amplifying RNA Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Self Amplifying RNA Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Self Amplifying RNA Vaccine Market Report

Report Metric	Details
Report Name	Self Amplifying RNA Vaccine Market
Accounted market size in year	US$ 417 million
Forecasted market size in 2031	US$ 587 million
CAGR	5.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Veterinary Use Self Amplifying RNA Vaccine Human Use Self Amplifying RNA Vaccine
Segment by Application	Hospital Clinic CDC Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Arcturus Therapeutics, CSL, Gennova Biopharmaceuticals, Genvax Technologies, Merck Animal Health, VLP Therapeutics, Chimeron Bio, Eyam Vaccines and Immunotherapeutics, Ziphius, Pfizer, BioNTech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Self Amplifying RNA Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Self Amplifying RNA Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Self Amplifying RNA Vaccine Market growing?

Ans: The Self Amplifying RNA Vaccine Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Self Amplifying RNA Vaccine Market size in 2031?

Ans: The Self Amplifying RNA Vaccine Market size in 2031 will be US$ 587 million.

Who are the main players in the Self Amplifying RNA Vaccine Market report?

Ans: The main players in the Self Amplifying RNA Vaccine Market are Arcturus Therapeutics, CSL, Gennova Biopharmaceuticals, Genvax Technologies, Merck Animal Health, VLP Therapeutics, Chimeron Bio, Eyam Vaccines and Immunotherapeutics, Ziphius, Pfizer, BioNTech

What are the Application segmentation covered in the Self Amplifying RNA Vaccine Market report?

Ans: The Applications covered in the Self Amplifying RNA Vaccine Market report are Hospital, Clinic, CDC, Others

What are the Type segmentation covered in the Self Amplifying RNA Vaccine Market report?

Ans: The Types covered in the Self Amplifying RNA Vaccine Market report are Veterinary Use Self Amplifying RNA Vaccine, Human Use Self Amplifying RNA Vaccine

1 Self Amplifying RNA Vaccine Market Overview

1.1 Product Definition

1.2 Self Amplifying RNA Vaccine by Type

1.2.1 Global Self Amplifying RNA Vaccine Market Value Comparison by Type (2024 VS 2031)

1.2.2 Veterinary Use Self Amplifying RNA Vaccine

1.2.3 Human Use Self Amplifying RNA Vaccine

1.3 Self Amplifying RNA Vaccine by Application

1.3.1 Global Self Amplifying RNA Vaccine Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 CDC

1.3.5 Others

1.4 Global Self Amplifying RNA Vaccine Market Size Estimates and Forecasts

1.4.1 Global Self Amplifying RNA Vaccine Revenue 2020-2031

1.4.2 Global Self Amplifying RNA Vaccine Sales 2020-2031

1.4.3 Global Self Amplifying RNA Vaccine Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Self Amplifying RNA Vaccine Market Competition by Manufacturers

2.1 Global Self Amplifying RNA Vaccine Sales Market Share by Manufacturers (2020-2025)

2.2 Global Self Amplifying RNA Vaccine Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Self Amplifying RNA Vaccine Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Self Amplifying RNA Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Self Amplifying RNA Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Self Amplifying RNA Vaccine, Product Type & Application

2.7 Global Key Manufacturers of Self Amplifying RNA Vaccine, Date of Enter into This Industry

2.8 Global Self Amplifying RNA Vaccine Market Competitive Situation and Trends

2.8.1 Global Self Amplifying RNA Vaccine Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Self Amplifying RNA Vaccine Players Market Share by Revenue

2.8.3 Global Self Amplifying RNA Vaccine Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Self Amplifying RNA Vaccine Market Scenario by Region

3.1 Global Self Amplifying RNA Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Self Amplifying RNA Vaccine Sales by Region: 2020-2031

3.2.1 Global Self Amplifying RNA Vaccine Sales by Region: 2020-2025

3.2.2 Global Self Amplifying RNA Vaccine Sales by Region: 2026-2031

3.3 Global Self Amplifying RNA Vaccine Revenue by Region: 2020-2031

3.3.1 Global Self Amplifying RNA Vaccine Revenue by Region: 2020-2025

3.3.2 Global Self Amplifying RNA Vaccine Revenue by Region: 2026-2031

3.4 North America Self Amplifying RNA Vaccine Market Facts & Figures by Country

3.4.1 North America Self Amplifying RNA Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Self Amplifying RNA Vaccine Sales by Country (2020-2031)

3.4.3 North America Self Amplifying RNA Vaccine Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Self Amplifying RNA Vaccine Market Facts & Figures by Country

3.5.1 Europe Self Amplifying RNA Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Self Amplifying RNA Vaccine Sales by Country (2020-2031)

3.5.3 Europe Self Amplifying RNA Vaccine Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Self Amplifying RNA Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific Self Amplifying RNA Vaccine Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Self Amplifying RNA Vaccine Sales by Region (2020-2031)

3.6.3 Asia Pacific Self Amplifying RNA Vaccine Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Self Amplifying RNA Vaccine Market Facts & Figures by Country

3.7.1 Latin America Self Amplifying RNA Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Self Amplifying RNA Vaccine Sales by Country (2020-2031)

3.7.3 Latin America Self Amplifying RNA Vaccine Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Self Amplifying RNA Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Self Amplifying RNA Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Self Amplifying RNA Vaccine Sales by Country (2020-2031)

3.8.3 Middle East and Africa Self Amplifying RNA Vaccine Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Self Amplifying RNA Vaccine Sales by Type (2020-2031)

4.1.1 Global Self Amplifying RNA Vaccine Sales by Type (2020-2025)

4.1.2 Global Self Amplifying RNA Vaccine Sales by Type (2026-2031)

4.1.3 Global Self Amplifying RNA Vaccine Sales Market Share by Type (2020-2031)

4.2 Global Self Amplifying RNA Vaccine Revenue by Type (2020-2031)

4.2.1 Global Self Amplifying RNA Vaccine Revenue by Type (2020-2025)

4.2.2 Global Self Amplifying RNA Vaccine Revenue by Type (2026-2031)

4.2.3 Global Self Amplifying RNA Vaccine Revenue Market Share by Type (2020-2031)

4.3 Global Self Amplifying RNA Vaccine Price by Type (2020-2031)

5 Segment by Application

5.1 Global Self Amplifying RNA Vaccine Sales by Application (2020-2031)

5.1.1 Global Self Amplifying RNA Vaccine Sales by Application (2020-2025)

5.1.2 Global Self Amplifying RNA Vaccine Sales by Application (2026-2031)

5.1.3 Global Self Amplifying RNA Vaccine Sales Market Share by Application (2020-2031)

5.2 Global Self Amplifying RNA Vaccine Revenue by Application (2020-2031)

5.2.1 Global Self Amplifying RNA Vaccine Revenue by Application (2020-2025)

5.2.2 Global Self Amplifying RNA Vaccine Revenue by Application (2026-2031)

5.2.3 Global Self Amplifying RNA Vaccine Revenue Market Share by Application (2020-2031)

5.3 Global Self Amplifying RNA Vaccine Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Arcturus Therapeutics

6.1.1 Arcturus Therapeutics Company Information

6.1.2 Arcturus Therapeutics Description and Business Overview

6.1.3 Arcturus Therapeutics Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Arcturus Therapeutics Self Amplifying RNA Vaccine Product Portfolio

6.1.5 Arcturus Therapeutics Recent Developments/Updates

6.2 CSL

6.2.1 CSL Company Information

6.2.2 CSL Description and Business Overview

6.2.3 CSL Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.2.4 CSL Self Amplifying RNA Vaccine Product Portfolio

6.2.5 CSL Recent Developments/Updates

6.3 Gennova Biopharmaceuticals

6.3.1 Gennova Biopharmaceuticals Company Information

6.3.2 Gennova Biopharmaceuticals Description and Business Overview

6.3.3 Gennova Biopharmaceuticals Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Gennova Biopharmaceuticals Self Amplifying RNA Vaccine Product Portfolio

6.3.5 Gennova Biopharmaceuticals Recent Developments/Updates

6.4 Genvax Technologies

6.4.1 Genvax Technologies Company Information

6.4.2 Genvax Technologies Description and Business Overview

6.4.3 Genvax Technologies Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Genvax Technologies Self Amplifying RNA Vaccine Product Portfolio

6.4.5 Genvax Technologies Recent Developments/Updates

6.5 Merck Animal Health

6.5.1 Merck Animal Health Company Information

6.5.2 Merck Animal Health Description and Business Overview

6.5.3 Merck Animal Health Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Merck Animal Health Self Amplifying RNA Vaccine Product Portfolio

6.5.5 Merck Animal Health Recent Developments/Updates

6.6 VLP Therapeutics

6.6.1 VLP Therapeutics Company Information

6.6.2 VLP Therapeutics Description and Business Overview

6.6.3 VLP Therapeutics Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.6.4 VLP Therapeutics Self Amplifying RNA Vaccine Product Portfolio

6.6.5 VLP Therapeutics Recent Developments/Updates

6.7 Chimeron Bio

6.7.1 Chimeron Bio Company Information

6.7.2 Chimeron Bio Description and Business Overview

6.7.3 Chimeron Bio Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Chimeron Bio Self Amplifying RNA Vaccine Product Portfolio

6.7.5 Chimeron Bio Recent Developments/Updates

6.8 Eyam Vaccines and Immunotherapeutics

6.8.1 Eyam Vaccines and Immunotherapeutics Company Information

6.8.2 Eyam Vaccines and Immunotherapeutics Description and Business Overview

6.8.3 Eyam Vaccines and Immunotherapeutics Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Eyam Vaccines and Immunotherapeutics Self Amplifying RNA Vaccine Product Portfolio

6.8.5 Eyam Vaccines and Immunotherapeutics Recent Developments/Updates

6.9 Ziphius

6.9.1 Ziphius Company Information

6.9.2 Ziphius Description and Business Overview

6.9.3 Ziphius Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Ziphius Self Amplifying RNA Vaccine Product Portfolio

6.9.5 Ziphius Recent Developments/Updates

6.10 Pfizer

6.10.1 Pfizer Company Information

6.10.2 Pfizer Description and Business Overview

6.10.3 Pfizer Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Pfizer Self Amplifying RNA Vaccine Product Portfolio

6.10.5 Pfizer Recent Developments/Updates

6.11 BioNTech

6.11.1 BioNTech Company Information

6.11.2 BioNTech Description and Business Overview

6.11.3 BioNTech Self Amplifying RNA Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.11.4 BioNTech Self Amplifying RNA Vaccine Product Portfolio

6.11.5 BioNTech Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Self Amplifying RNA Vaccine Industry Chain Analysis

7.2 Self Amplifying RNA Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Self Amplifying RNA Vaccine Production Mode & Process Analysis

7.4 Self Amplifying RNA Vaccine Sales and Marketing

7.4.1 Self Amplifying RNA Vaccine Sales Channels

7.4.2 Self Amplifying RNA Vaccine Distributors

7.5 Self Amplifying RNA Vaccine Customer Analysis

8 Self Amplifying RNA Vaccine Market Dynamics

8.1 Self Amplifying RNA Vaccine Industry Trends

8.2 Self Amplifying RNA Vaccine Market Drivers

8.3 Self Amplifying RNA Vaccine Market Challenges

8.4 Self Amplifying RNA Vaccine Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Arcturus Therapeutics

Gennova Biopharmaceuticals

Eyam Vaccines and Immunotherapeutics

Ziphius

List of Tables

Table 1. Global Self Amplifying RNA Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Self Amplifying RNA Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Self Amplifying RNA Vaccine Market Competitive Situation by Manufacturers in 2024

Table 4. Global Self Amplifying RNA Vaccine Sales (Units) of Key Manufacturers (2020-2025)

Table 5. Global Self Amplifying RNA Vaccine Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Self Amplifying RNA Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Self Amplifying RNA Vaccine Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Self Amplifying RNA Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Self Amplifying RNA Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Self Amplifying RNA Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Self Amplifying RNA Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Self Amplifying RNA Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Self Amplifying RNA Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Self Amplifying RNA Vaccine as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Self Amplifying RNA Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Self Amplifying RNA Vaccine Sales by Region (2020-2025) & (Units)

Table 18. Global Self Amplifying RNA Vaccine Sales Market Share by Region (2020-2025)

Table 19. Global Self Amplifying RNA Vaccine Sales by Region (2026-2031) & (Units)

Table 20. Global Self Amplifying RNA Vaccine Sales Market Share by Region (2026-2031)

Table 21. Global Self Amplifying RNA Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Self Amplifying RNA Vaccine Revenue Market Share by Region (2020-2025)

Table 23. Global Self Amplifying RNA Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Self Amplifying RNA Vaccine Revenue Market Share by Region (2026-2031)

Table 25. North America Self Amplifying RNA Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Self Amplifying RNA Vaccine Sales by Country (2020-2025) & (Units)

Table 27. North America Self Amplifying RNA Vaccine Sales by Country (2026-2031) & (Units)

Table 28. North America Self Amplifying RNA Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Self Amplifying RNA Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Self Amplifying RNA Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Self Amplifying RNA Vaccine Sales by Country (2020-2025) & (Units)

Table 32. Europe Self Amplifying RNA Vaccine Sales by Country (2026-2031) & (Units)

Table 33. Europe Self Amplifying RNA Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Self Amplifying RNA Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Self Amplifying RNA Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Self Amplifying RNA Vaccine Sales by Region (2020-2025) & (Units)

Table 37. Asia Pacific Self Amplifying RNA Vaccine Sales by Region (2026-2031) & (Units)

Table 38. Asia Pacific Self Amplifying RNA Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Self Amplifying RNA Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Self Amplifying RNA Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Self Amplifying RNA Vaccine Sales by Country (2020-2025) & (Units)

Table 42. Latin America Self Amplifying RNA Vaccine Sales by Country (2026-2031) & (Units)

Table 43. Latin America Self Amplifying RNA Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Self Amplifying RNA Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Self Amplifying RNA Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Self Amplifying RNA Vaccine Sales by Country (2020-2025) & (Units)

Table 47. Middle East and Africa Self Amplifying RNA Vaccine Sales by Country (2026-2031) & (Units)

Table 48. Middle East and Africa Self Amplifying RNA Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Self Amplifying RNA Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Self Amplifying RNA Vaccine Sales (Units) by Type (2020-2025)

Table 51. Global Self Amplifying RNA Vaccine Sales (Units) by Type (2026-2031)

Table 52. Global Self Amplifying RNA Vaccine Sales Market Share by Type (2020-2025)

Table 53. Global Self Amplifying RNA Vaccine Sales Market Share by Type (2026-2031)

Table 54. Global Self Amplifying RNA Vaccine Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Self Amplifying RNA Vaccine Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Self Amplifying RNA Vaccine Revenue Market Share by Type (2020-2025)

Table 57. Global Self Amplifying RNA Vaccine Revenue Market Share by Type (2026-2031)

Table 58. Global Self Amplifying RNA Vaccine Price (US$/Unit) by Type (2020-2025)

Table 59. Global Self Amplifying RNA Vaccine Price (US$/Unit) by Type (2026-2031)

Table 60. Global Self Amplifying RNA Vaccine Sales (Units) by Application (2020-2025)

Table 61. Global Self Amplifying RNA Vaccine Sales (Units) by Application (2026-2031)

Table 62. Global Self Amplifying RNA Vaccine Sales Market Share by Application (2020-2025)

Table 63. Global Self Amplifying RNA Vaccine Sales Market Share by Application (2026-2031)

Table 64. Global Self Amplifying RNA Vaccine Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Self Amplifying RNA Vaccine Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Self Amplifying RNA Vaccine Revenue Market Share by Application (2020-2025)

Table 67. Global Self Amplifying RNA Vaccine Revenue Market Share by Application (2026-2031)

Table 68. Global Self Amplifying RNA Vaccine Price (US$/Unit) by Application (2020-2025)

Table 69. Global Self Amplifying RNA Vaccine Price (US$/Unit) by Application (2026-2031)

Table 70. Arcturus Therapeutics Company Information

Table 71. Arcturus Therapeutics Description and Business Overview

Table 72. Arcturus Therapeutics Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Arcturus Therapeutics Self Amplifying RNA Vaccine Product

Table 74. Arcturus Therapeutics Recent Developments/Updates

Table 75. CSL Company Information

Table 76. CSL Description and Business Overview

Table 77. CSL Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. CSL Self Amplifying RNA Vaccine Product

Table 79. CSL Recent Developments/Updates

Table 80. Gennova Biopharmaceuticals Company Information

Table 81. Gennova Biopharmaceuticals Description and Business Overview

Table 82. Gennova Biopharmaceuticals Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Gennova Biopharmaceuticals Self Amplifying RNA Vaccine Product

Table 84. Gennova Biopharmaceuticals Recent Developments/Updates

Table 85. Genvax Technologies Company Information

Table 86. Genvax Technologies Description and Business Overview

Table 87. Genvax Technologies Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Genvax Technologies Self Amplifying RNA Vaccine Product

Table 89. Genvax Technologies Recent Developments/Updates

Table 90. Merck Animal Health Company Information

Table 91. Merck Animal Health Description and Business Overview

Table 92. Merck Animal Health Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Merck Animal Health Self Amplifying RNA Vaccine Product

Table 94. Merck Animal Health Recent Developments/Updates

Table 95. VLP Therapeutics Company Information

Table 96. VLP Therapeutics Description and Business Overview

Table 97. VLP Therapeutics Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. VLP Therapeutics Self Amplifying RNA Vaccine Product

Table 99. VLP Therapeutics Recent Developments/Updates

Table 100. Chimeron Bio Company Information

Table 101. Chimeron Bio Description and Business Overview

Table 102. Chimeron Bio Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Chimeron Bio Self Amplifying RNA Vaccine Product

Table 104. Chimeron Bio Recent Developments/Updates

Table 105. Eyam Vaccines and Immunotherapeutics Company Information

Table 106. Eyam Vaccines and Immunotherapeutics Description and Business Overview

Table 107. Eyam Vaccines and Immunotherapeutics Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Eyam Vaccines and Immunotherapeutics Self Amplifying RNA Vaccine Product

Table 109. Eyam Vaccines and Immunotherapeutics Recent Developments/Updates

Table 110. Ziphius Company Information

Table 111. Ziphius Description and Business Overview

Table 112. Ziphius Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Ziphius Self Amplifying RNA Vaccine Product

Table 114. Ziphius Recent Developments/Updates

Table 115. Pfizer Company Information

Table 116. Pfizer Description and Business Overview

Table 117. Pfizer Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Pfizer Self Amplifying RNA Vaccine Product

Table 119. Pfizer Recent Developments/Updates

Table 120. BioNTech Company Information

Table 121. BioNTech Description and Business Overview

Table 122. BioNTech Self Amplifying RNA Vaccine Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. BioNTech Self Amplifying RNA Vaccine Product

Table 124. BioNTech Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. Self Amplifying RNA Vaccine Distributors List

Table 128. Self Amplifying RNA Vaccine Customers List

Table 129. Self Amplifying RNA Vaccine Market Trends

Table 130. Self Amplifying RNA Vaccine Market Drivers

Table 131. Self Amplifying RNA Vaccine Market Challenges

Table 132. Self Amplifying RNA Vaccine Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Product Picture of Self Amplifying RNA Vaccine

Figure 2. Global Self Amplifying RNA Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Self Amplifying RNA Vaccine Market Share by Type: 2024 & 2031

Figure 4. Veterinary Use Self Amplifying RNA Vaccine Product Picture

Figure 5. Human Use Self Amplifying RNA Vaccine Product Picture

Figure 6. Global Self Amplifying RNA Vaccine Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Self Amplifying RNA Vaccine Market Share by Application: 2024 & 2031

Figure 8. Hospital

Figure 9. Clinic

Figure 10. CDC

Figure 11. Others

Figure 12. Global Self Amplifying RNA Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Self Amplifying RNA Vaccine Market Size (2020-2031) & (US$ Million)

Figure 14. Global Self Amplifying RNA Vaccine Sales (2020-2031) & (Units)

Figure 15. Global Self Amplifying RNA Vaccine Average Price (US$/Unit) & (2020-2031)

Figure 16. Self Amplifying RNA Vaccine Report Years Considered

Figure 17. Self Amplifying RNA Vaccine Sales Share by Manufacturers in 2024

Figure 18. Global Self Amplifying RNA Vaccine Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Self Amplifying RNA Vaccine Players: Market Share by Revenue in Self Amplifying RNA Vaccine in 2024

Figure 20. Self Amplifying RNA Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Self Amplifying RNA Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Self Amplifying RNA Vaccine Sales Market Share by Country (2020-2031)

Figure 23. North America Self Amplifying RNA Vaccine Revenue Market Share by Country (2020-2031)

Figure 24. United States Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Self Amplifying RNA Vaccine Sales Market Share by Country (2020-2031)

Figure 27. Europe Self Amplifying RNA Vaccine Revenue Market Share by Country (2020-2031)

Figure 28. Germany Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Self Amplifying RNA Vaccine Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Self Amplifying RNA Vaccine Revenue Market Share by Region (2020-2031)

Figure 35. China Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. China Taiwan Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Southeast Asia Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Latin America Self Amplifying RNA Vaccine Sales Market Share by Country (2020-2031)

Figure 43. Latin America Self Amplifying RNA Vaccine Revenue Market Share by Country (2020-2031)

Figure 44. Mexico Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Brazil Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Argentina Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Colombia Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Self Amplifying RNA Vaccine Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Self Amplifying RNA Vaccine Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE Self Amplifying RNA Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Self Amplifying RNA Vaccine by Type (2020-2031)

Figure 54. Global Revenue Market Share of Self Amplifying RNA Vaccine by Type (2020-2031)

Figure 55. Global Self Amplifying RNA Vaccine Price (US$/Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of Self Amplifying RNA Vaccine by Application (2020-2031)

Figure 57. Global Revenue Market Share of Self Amplifying RNA Vaccine by Application (2020-2031)

Figure 58. Global Self Amplifying RNA Vaccine Price (US$/Unit) by Application (2020-2031)

Figure 59. Self Amplifying RNA Vaccine Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Self replicating mRNA Vaccines Market Research Report 2024

Global Self amplifying RNA saRNA Drugs Market Research Report 2024

Messenger RNA Vaccines and Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global RNA Vaccines Market Insights Forecast to 2030

Global saRNA Synthesis Service Market Research Report 2025

Global Non Replicating mRNA Vaccine Market Research Report 2025

Global Livestock mRNA Vaccines Market Research Report 2025

Global RSV mRNA Vaccine Market Research Report 2025

Global mRNA Vaccines Therapeutics Market Research Report 2024

Global mRNA Vaccines for Animals Market Research Report 2025

Global mRNA Vaccine And Therapeutics Market Insights Forecast to 2030

Global Autogenous Vaccines Market Insights Forecast to 2030

mRNA Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Nucleic Acid Vaccine Market Insights Forecast to 2030

Global mRNA Cancer Vaccines and Therapeutics Market Insights Forecast to 2030

Global Nucleic Vaccine Market Insights Forecast to 2030

Global mRNA Vaccine Raw Materials Market Research Report 2024

Global mRNA Therapy Market Research Report 2024

mRNA Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions